News | Proton Therapy | March 13, 2019

What to Expect from the Proton Therapy Market in 2019-2020

Sales decline continued in 2018, but interest remains high despite financial barriers

What to Expect from the Proton Therapy Market in 2019-2020

March 13, 2019 — The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new report from MEDraysintell, continuing a trend dating back to mid-2016. The report says this trend may change if particle therapy vendors are able to build a strong order book in 2019 and 2020.

Following the large number of new orders for proton therapy equipment reported worldwide during the year 2015, MEDraysintell considered that it was facing a market with strong potential. This positive trend continued until mid-2016, when it began to slow down with a persistent decline in 2017, further confirmed in 2018 as well. Overall, 2018 sales dropped by 62 percent compared to 2015. This decline impacts directly the particle therapy market size (in value by U.S. dollars) evolution, with an anticipated market slowdown of some 25 percent in 2020 compared to 2018. The year 2018 also clearly confirmed the trend in favor of single-room facilities, with 100 percent of the proton therapy orders worldwide oriented towards single-room facilities (compared to less than 40 percent in 2016).

However, a retrospective analysis shows that 2015 was an exceptional year with a record level of orders, and not the new standard expected by the industry, according to the MEDraysintell report. In general, negative publicity, resistance from health authorities and private insurances to reimburse proton therapy, and cost hurdles as a whole have certainly been important factors in the slow adoption of proton therapy facilities in the recent past, the report said. This limited support from investors and healthcare payers remains unchanged and linked to both the higher price of this modality compared to external radiotherapy and the lack of definitive clinical demonstration of superiority (which is under progress).

As of February 2019, there were fewer than 240 particle therapy (mostly proton therapy) treatment rooms available to patients worldwide. This low number represents only 0.3 particle therapy treatment rooms per 10 million people compared to roughly an equivalent 20 radiotherapy systems in the world.

In order to sustain the market growth and to increase the use of proton therapy as an efficient cancer treatment, the PT industry should encourage the research, collection and ongoing publication of clinical evidence, according to MEDraysintell. In addition, stronger marketing is needed in order to grow the referencing of patients toward proton therapy centers. Some mixed signals from the proton therapy area have already been observed — for instance a growing interest of the medical-scientific community stating that at least 10 percent of the population requiring external radiotherapy treatment could benefit from proton therapy. However, this level reached only 0.7 percent in 2018 and almost all operational particle therapy centers are far from saturation levels, with only 17 percent of them able to treat on average over 200 patients per treatment room.

For more information: www.medraysintell.com

Related Proton Therapy Content

VIDEO: Economics of Proton Therapy

VIDEO: The Role of the Physicist in Proton Therapy

360 View of the Gantry Room at the Northwestern Medicine Chicago Proton Center

360 View of the Inclined Beam Room at the Northwestern Medicine Chicago Proton Center

Related Content

Elekta Harmony linear accelerator cleared by U.S. Food and Drug Administration
News | Linear Accelerators | June 18, 2021
June 18, 2021 — Elekta announced that its Elekta Harmony...
The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | Artificial Intelligence | June 15, 2021
June 15, 2021 — The impact of deploying ...
Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | Radiation Therapy | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

News | Radiation Oncology | June 02, 2021
June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional rad
The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

News | Radiation Therapy | May 21, 2021
May 21, 2021 — An experimental drug that has shown promise in protecting healthy tissue from collateral damage caused
The drug, known as Avasopasem manganese, is made by Galera Therapeutics. It acts like a natural enzyme called superoxide dismutase and converts superoxide into hydrogen peroxide. Based on its ability to "mop up" damaging superoxide molecules, which are produced by radiation treatment, the drug is currently in clinical trials to test its ability to protect mucosal tissue from the side-effect of radiotherapy.

Getty Images

News | Radiation Therapy | May 19, 2021
May 19, 2021 — A small drug molecule that appears to protect normal tissue from the damaging effects of...